DMAC · DiaMedica Therapeutics Inc.

DiaMedica Therapeutics announced its full-year 2025 financial results on March 30, 2026, via Exhibit 99.1 press release, highlighting clinical progress alongside increased operating losses. Net loss widened to $32.8 million ($0.70 per share) from $24.4 million ($0.60 per share) in 2024, driven by R&D expenses rising 29% to $24.6 million, primarily from ReMEDy2 Phase 2/3 acute ischemic stroke trial expansion including global sites and clinical team growth, partially offset by prior manufacturing efficiencies. G&A expenses increased 28% to $9.8 million due to higher share-based compensation, personnel, investor relations, and patent costs. Operating cash use rose to $29.1 million from $22.1 million, reflecting the net loss expansion. Balance sheet strengthened with cash, equivalents, and investments at $59.9 million (up from $44.1 million) via July 2025 private placement and at-the-market offerings, funding operations through 2H 2027. CEO Rick Pauls emphasized DM199 preeclampsia program advances, including Health Canada NOL for company-sponsored Phase 2 in early-onset preeclampsia, ongoing IST Part 1a enrollment (completion 1H 2026), and ReMEDy2 nearing 70% interim enrollment for 2H 2026 analysis. Management anticipates moderate R&D increases and steady/slight G&A rises as trials progress, positioning for key 2026 milestones without near-term financing needs.